waldenstrom macroglobulinemia market insight

DelveInsight’s ‘Waldenstrom Macroglobulinemia (WM)—Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Waldenstrom Macroglobulinemia, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Waldenstrom Macroglobulinemia (WM) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Waldenstrom Macroglobulinemia symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Waldenstrom Macroglobulinemia symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030

Waldenstrom Macroglobulinemia (WM) Disease Understanding and Treatment Algorithm

Waldenstrom Macroglobulinemia (WM) Overview

Waldenstrom Macroglobulinemia, also referred to as a lymphoplasmacytic lymphoma (LPL) with an associated monoclonal IgM paraprotein, is a rare indolent (slow-growing) B-cell lymphoma that occurs in <2% of patients with Non-Hodgkin’s Lymphoma (NHL). This usually affects older adults and generally affects the bone marrow but can also occur in the lymph nodes and other tissues and organs of the lymphatic system.

Waldenstrom Macroglobulinemia (WM) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Waldenstrom Macroglobulinemia market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Waldenstrom Macroglobulinemia market report thoroughly understands Waldenstrom Macroglobulinemia symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Waldenstrom Macroglobulinemia treatment algorithms and treatment guidelines for Waldenstrom Macroglobulinemia symptoms in the US, Europe, and Japan.

There are numerous treatment options available for the symptomatic patient pool of Waldenstrom Macroglobulinemia such as Plasmapheresis, Targeted therapy, chemotherapy, chemoimmunotherapy, and Stem cell transplantation/bone marrow transplantation.

IMBRUVICA (ibrutinib), the first-generation BTK inhibitor, is the first drug to be approved in the US (2015) and EU, for the treatment of symptomatic Waldenstrom Macroglobulinemia. Treatment may consist of just one drug (single-agent therapy) or two or more drugs (combination therapy), for enhanced efficacy and longer-lasting responses. The treatment options include alkylating agents (e.g. chlorambucil, and cyclophosphamide), nucleoside analog (fludarabine and cladribine), the monoclonal antibody rituximab, and the proteasome inhibitor bortezomib.

However, the unmet needs including lack of curative therapies, need for therapies with minimal toxicity profile, high clinical and economic burden, and high cost of approved therapies, are driving opportunities in the market.

Waldenstrom Macroglobulinemia (WM) Epidemiology

The Waldenstrom Macroglobulinemia symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

Key Findings

The total incident cases of Waldenstrom Macroglobulinemia is increased by 7MM during the study period, i.e., 2018–2030.

The disease epidemiology covered in the report provides historical as well as forecasted Waldenstrom Macroglobulinemia (WM) symptoms epidemiology segmented as the Incidence of Waldenstrom Macroglobulinemia, Gender-specific cases of Waldenstrom Macroglobulinemia, Age-specific Cases of Waldenstrom Macroglobulinemia, and Genetic Mutations in Waldenstrom Macroglobulinemia. The report includes the incident scenario of Waldenstrom Macroglobulinemia (WM) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Waldenstrom Macroglobulinemia (WM) Epidemiology

The epidemiology segment also provides the Waldenstrom Macroglobulinemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total number of incident cases of Waldenstrom Macroglobulinemia associated in 7MM countries was 3,159 in 2020.

Waldenstrom Macroglobulinemia (WM) Drug Chapters

The Waldenstrom Macroglobulinemia report’s drug chapter segment encloses the detailed analysis of Waldenstrom Macroglobulinemia early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Waldenstrom Macroglobulinemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Waldenstrom Macroglobulinemia (WM) Emerging Drug

Zanubrutinib: BeiGene

Zanubrutinib (BGB-3111) — an inhibitor of Bruton’s tyrosine kinase, or BTK is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. BTK is a key component of the B-cell receptor, or BCR, signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies. BTK inhibitors block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in certain malignant white blood cells called B-cells. Zanubrutinib is an orally active inhibitor that covalently binds to BTK, resulting in irreversible inactivation of the enzyme.

Acalabrutinib: AstraZeneca

Acalabrutinib (also known as ACP-196) is an orally administered small molecule that covalently binds to Cys481 in the ATP-binding pocket of Bruton’s tyrosine kinase (BTK). It is a highly selective and potent covalent inhibitor of BTK and has minimal impact on other kinases like Tec, ITK, TXK, and EGFR. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways leading to an inhibition of the growth of malignant B cells that overexpress BTK.

Products detail in the report…

Waldenstrom Macroglobulinemia (WM) Market Outlook

The report’s market outlook helps build a detailed comprehension of the historic, current, and forecasted Waldenstrom Macroglobulinemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Waldenstrom Macroglobulinemia market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

According to DelveInsight, the Waldenstrom Macroglobulinemia market in 7MM is expected to grow in the study period 2018–2030.

There are numerous treatment options available for the symptomatic patient pool of Waldenstrom Macroglobulinemia such as plasmapheresis, Targeted therapy, chemotherapy, chemoimmunotherapy, and Stem cell transplantation/bone marrow transplantation. The treatment decisions are based on the severity of symptoms, patient factors including age and functional status, and disease factors including the presence of cytopenias, the rate of disease progression, the level of IgM protein, and the presence of neuropathy.

Treatment may consist of just one drug (single-agent therapy) or two or more drugs (combination therapy). Most studies seem to indicate that combination therapies are more effective, resulting in better and/or longer-lasting responses. The treatment options for Waldenstrom Macroglobulinemia mostly include alkylating agents (e.g. chlorambucil, and cyclophosphamide), nucleoside analog (fludarabine and cladribine), the monoclonal antibody rituximab, and the proteasome inhibitor bortezomib. Chemotherapy followed by the use of Rituximab as a monotherapy or in combination is a primary treatment method, adapted by many.

Key Findings

This section includes a glimpse of the Waldenstrom Macroglobulinemia market in 7MM.

Waldenstrom Macroglobulinemia market size in the seven major markets was USD 134.6 million in 2020.

The United States Market Outlook

This section provides the total Waldenstrom Macroglobulinemia market size and market size by therapies in the United States.

The United States accounts for the largest market size of Waldenstrom Macroglobulinemia in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Waldenstrom Macroglobulinemia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Waldenstrom Macroglobulinemia market Size and market Size by therapies in Japan are also mentioned.

Waldenstrom Macroglobulinemia (WM) Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the Waldenstrom Macroglobulinemia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Waldenstrom Macroglobulinemia (WM) Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Waldenstrom Macroglobulinemia key players involved in developing targeted therapeutics.

Major players include BeiGene, AstraZeneca, and others.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Waldenstrom Macroglobulinemia emerging therapies.

Reimbursement Scenario in Waldenstrom Macroglobulinemia (WM)

Approaching reimbursement proactively can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

The high treatment costs, including chemo and other therapies, affect patients’ affordability and access to these treatment options. Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the drug price relative to the benefit it produces in treated patients.

The disease advocacy groups working in the area of Waldenstrom Macroglobulinemia helps patients with medical billing, insurance coverage, and reimbursement issues. Also, financial assistance is available from both governments and pharmaceutical companies to help people who cannot afford the cost of their medications.

IMBRUVICA by Side Patient Support Program

It offers personalized support to help patients access and stay on track with their prescribed treatment. It is built to encourage patients to help them stick to the treatment prescribed by the physician.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Waldenstrom Macroglobulinemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Waldenstrom Macroglobulinemia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Waldenstrom Macroglobulinemia Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Waldenstrom Macroglobulinemia, explaining its causes, signs and symptoms, physiology, and currently available therapies.
• Comprehensive insight has been provided into the Waldenstrom Macroglobulinemia epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Waldenstrom Macroglobulinemia is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
• A detailed review of the Waldenstrom Macroglobulinemia market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Waldenstrom Macroglobulinemia market.

Report Highlights

• In the coming years, the Waldenstrom Macroglobulinemia market is set to change due to the rising awareness of the disease, and the Favorable Environment for New Anti-infective Modalities; which would expand the market’s size to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Waldenstrom Macroglobulinemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Waldenstrom Macroglobulinemia. The launch of emerging therapies will significantly impact the Waldenstrom Macroglobulinemia market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Waldenstrom Macroglobulinemia (WM) Report Insights

• Patient Population
• Therapeutic Approaches
• Waldenstrom Macroglobulinemia Pipeline Analysis
• Waldenstrom Macroglobulinemia Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Waldenstrom Macroglobulinemia (WM) Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Waldenstrom Macroglobulinemia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Waldenstrom Macroglobulinemia (WM) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Waldenstrom Macroglobulinemia Market share (%) distribution in 2018, and how it would look like in 2030?
• What would be the Waldenstrom Macroglobulinemia total market size and market size by therapies across the 7MM during the forecast period (2018–2030)?
• What are the key findings of the market across 7MM, and which country will have the largest Waldenstrom Macroglobulinemia market Size during the forecast period (2018–2030)?
• At what CAGR, the Waldenstrom Macroglobulinemia market is expected to grow in 7MM during the forecast period (2018–2030)?
• What would be the Waldenstrom Macroglobulinemia market outlook across the 7MM during the forecast period (2018–2030)?
• What would be the Waldenstrom Macroglobulinemia market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of Waldenstrom Macroglobulinemia?
• What is the historical Waldenstrom Macroglobulinemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Waldenstrom Macroglobulinemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about Waldenstrom Macroglobulinemia?
• Out of all 7MM countries, which country would have the largest incident population of Waldenstrom Macroglobulinemia during the forecast period (2018–2030)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2018–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Waldenstrom Macroglobulinemia along with the approved therapy?
• What are the current treatment guidelines for treating Waldenstrom Macroglobulinemia in the USA, Europe, and Japan?
• What are the Waldenstrom Macroglobulinemia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Waldenstrom Macroglobulinemia?
• How many therapies are developed by each company for the treatment of Waldenstrom Macroglobulinemia?
• How many emerging therapies are in the mid-stage and late stages of development to treat Waldenstrom Macroglobulinemia?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Waldenstrom Macroglobulinemia therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Waldenstrom Macroglobulinemia and their status?
• What are the key designations that have been granted for the emerging therapies for Waldenstrom Macroglobulinemia?
• What are the global historical and forecasted market of Waldenstrom Macroglobulinemia?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Waldenstrom Macroglobulinemia market.
• To understand the future market competition in the Waldenstrom Macroglobulinemia market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Waldenstrom Macroglobulinemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Waldenstrom Macroglobulinemia market.
• To understand the future market competition in the Waldenstrom Macroglobulinemia market.